These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2274639)

  • 21. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 22. Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
    Sedvall G; Fyrö B; Nybäck H; Wiesel FA; Wode-Helgodt B
    J Psychiatr Res; 1974; 11():75-80. PubMed ID: 4461807
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathophysiological studies on schizophrenia with special reference to homovanillic acid concentration in cerebrospin fluid.
    Shimizu T
    Bull Osaka Med Sch; 1979 Jul; 25(1):51-68. PubMed ID: 540184
    [No Abstract]   [Full Text] [Related]  

  • 24. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.
    Tamminga CA; Littman RL; Alphs LD; Chase TN; Thaker GK; Wagman AM
    Psychopharmacology (Berl); 1986; 88(3):387-91. PubMed ID: 3083460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Condray R; Peters JL
    Neuropsychopharmacology; 1996 Apr; 14(4):275-83. PubMed ID: 8924195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
    Rasmussen K; Stockton ME; Czachura JF; Howbert JJ
    Eur J Pharmacol; 1991 Dec; 209(1-2):135-8. PubMed ID: 1687681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholecystokinin and schizophrenia.
    Nair NP; Lal S; Bloom DM
    Prog Brain Res; 1986; 65():237-58. PubMed ID: 3538160
    [No Abstract]   [Full Text] [Related]  

  • 28. Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment.
    Sharma RP; Javaid JI; Janicak PG; Davis JM; Faull K
    Biol Psychiatry; 1993 Aug; 34(3):128-34. PubMed ID: 8104508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia.
    Lotstra F; Verbanck PM; Gilles C; Mendlewicz J; Vanderhaeghen JJ
    Ann N Y Acad Sci; 1985; 448():507-17. PubMed ID: 3896098
    [No Abstract]   [Full Text] [Related]  

  • 30. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
    Rasmussen K
    Ann N Y Acad Sci; 1994 Mar; 713():300-11. PubMed ID: 8185172
    [No Abstract]   [Full Text] [Related]  

  • 33. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients.
    Licinio J; Seibyl JP; Altemus M; Charney DS; Krystal JH
    Am J Psychiatry; 1993 Sep; 150(9):1408-10. PubMed ID: 8102512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites.
    Lindström LH; Besev G; Gunne LM; Terenius L
    Psychiatry Res; 1986 Oct; 19(2):93-100. PubMed ID: 2431427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholecystokinin and neurotensin gradients in human CSF.
    Tamminga CA; LeWitt PA; Chase TN
    Arch Neurol; 1985 Apr; 42(4):354-5. PubMed ID: 3985812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
    Innis RB; Bunney BS; Charney DS; Price LH; Glazer WM; Sternberg DE; Rubin AL; Heninger GR
    Psychiatry Res; 1986 May; 18(1):1-7. PubMed ID: 3737785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
    Doran AR; Rubinow DR; Wolkowitz OM; Roy A; Breier A; Pickar D
    Biol Psychiatry; 1989 Feb; 25(4):431-9. PubMed ID: 2564787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of cholecystokinin in schizophrenia: a review.
    Montgomery SA; Green MC
    Psychol Med; 1988 Aug; 18(3):593-603. PubMed ID: 3054990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF cholecystokinin, gamma-aminobutyric acid and neuropeptide Y in pathological gamblers and healthy controls.
    Nordin C; Sjödin I
    J Neural Transm (Vienna); 2007; 114(4):499-503. PubMed ID: 17109076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.